A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: Blinded pooled interim safety data from the ENGOT-OV26/PRIMA study

Journal article

Peer reviewed

B.J. Monk, M.R. Mirza, I. Vergote, Y. Li, I. Malinowska, D. Gupta, W.A. Graybill, B. Pothuri and A. Gonzalez-Martin

Gynecologic oncology, Vol.154, pp.3-4

06/2019

Metrics

4 Record Views

Title: A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: Blinded pooled interim safety data from the ENGOT-OV26/PRIMA study
Creators: B.J. Monk - Creighton University
M.R. Mirza - Nordic Society of Gynecologic Oncology
I. Vergote - KU Leuven
Y. Li - Tesaro
I. Malinowska - Tesaro
D. Gupta - Tesaro
W.A. Graybill - Medical University of South Carolina
B. Pothuri - NYU Langone Health
A. Gonzalez-Martin - Clinica Universidad de Navarra
Publication Details: Gynecologic oncology, Vol.154, pp.3-4
Publisher: Elsevier Inc
Identifiers: 991005969045002656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article